Ovagen

Ovagen — Liver and GI Bioregulator Tripeptide by Dragon Pharma

Ovagen (Glu-Asp-Glu) is Dragon Pharma's formulation of the hepatic and gastrointestinal Khavinson bioregulator tripeptide at 20mg per vial — the liver-targeted entry point in the Khavinson peptide bioregulator series. Developed at the St. Petersburg Institute of Bioregulation and Gerontology alongside Livagen (immune bioregulator) and other tissue-specific bioregulators, Ovagen specifically targets hepatocyte and gastrointestinal mucosal gene expression through the same epigenetic DNA demethylation mechanism shared by the Khavinson series — but with tissue specificity for liver and gut rather than immune tissue.

Also searched as: Ovagen peptide, Glu-Asp-Glu bioregulator, Ovagen liver peptide, Khavinson liver bioregulator, Ovagen Dragon Pharma.

Ovagen in the Khavinson Bioregulator Framework

Ovagen cannot be fully understood without understanding the broader Khavinson bioregulator framework:

• The Khavinson bioregulators are tissue-specific short peptides derived from organ extracts, each targeting the tissue from which they were derived. The tissue specificity is a defining feature — Ovagen (derived from liver/GI tissue) acts preferentially in hepatocytes and GI mucosa; Livagen (from lymphoid tissue) acts in immune cells; Epitalon (from pineal tissue) acts on the pineal axis
• All Khavinson bioregulators share the same proposed mechanism: direct interaction with DNA and chromatin in target tissue cells, promoting DNA demethylation of silenced gene promoters and restoring gene expression patterns that decline with age or tissue damage
• In the liver context: aging, chronic toxin exposure (including 17-AA oral AAS hepatotoxicity), viral hepatitis and fatty liver disease all produce epigenetic silencing of hepatocyte genes involved in detoxification, regeneration and cellular homeostasis. Ovagen's proposed action is to reverse this silencing — reactivating the gene expression programme of healthy, younger hepatocytes

Why Ovagen Is Specifically Relevant for AAS Users

This is the most directly AAS-relevant aspect of Ovagen and the information gap most competitor content leaves entirely unfilled:

• 17-Alpha Alkylated Oral AAS Hepatotoxicity: Oral 17-AA AAS — Dianabol, Winstrol, Anadrol, Superdrol, Halotestin, Oral Tren, M1T — produce hepatotoxicity through first-pass hepatic stress, cholestasis, and direct hepatocyte stress. ALT/AST elevation is rapid and pronounced. During and after oral AAS cycles, hepatocyte gene expression is disrupted — including genes involved in the detoxification, anti-inflammatory response and regeneration that hepatocytes rely on
• Ovagen's hepatoprotective mechanism addresses this at the epigenetic level — reactivating the silenced hepatocyte genes that AAS hepatotoxicity suppresses, potentially accelerating hepatic function recovery after cycles
• While conventional hepatoprotectants (TUDCA, UDCA, NAC, milk thistle) work through established antioxidant and bile salt pathways, Ovagen works at the gene expression level — a complementary and mechanistically distinct approach
• GI mucosal protection: Oral AAS and NSAIDs (often used by athletes) both damage GI mucosal layers. Ovagen's GI tissue specificity extends hepatic protection to the full upper GI tract — stomach and intestinal mucosal cell gene expression

Liver Protection Comparison — Conventional vs Ovagen

The GI Tract Component

Ovagen's GI tract activity is its second major mechanism and rarely discussed:

• The GI mucosal lining — from oesophagus through stomach to intestine — is subject to rapid cell turnover and is highly sensitive to disruption from oral AAS, NSAIDs, alcohol, and dietary stress that AAS users experience
• Mucosal cells in the GI tract, like hepatocytes, show age-related epigenetic silencing of genes involved in mucus production, tight junction integrity and inflammatory regulation
• Ovagen's tissue affinity for GI mucosal tissue (from its organ-extract derivation) produces chromatin-level gene reactivation in these cells, potentially restoring the gene expression patterns that maintain mucosal barrier integrity and resistance to ulceration

Effects and Benefits

• Hepatocyte gene expression restoration via DNA demethylation — reactivation of detoxification, regeneration and homeostasis genes silenced by aging or toxic exposure
• Liver support during and after AAS cycles — targeted at the epigenetic level rather than through antioxidant or bile salt mechanisms
• GI mucosal protection and gene reactivation — extended benefit to the full upper GI tract
• Complementary to conventional hepatoprotectants (TUDCA, NAC) — different mechanism, additive rather than redundant protection
• No testosterone suppression — no PCT required

Dosage and Administration

At 20mg per vial and 200mcg per dose, one vial provides 100 doses — approximately 3+ months of daily dosing or multiple annual courses. Following the Khavinson course-based approach (10-20 day intensive protocols) rather than continuous use is standard. Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated at 2-8°C for up to 28 days.